Journal
LANCET
Volume 389, Issue 10065, Pages 197-210Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(16)30677-8
Keywords
-
Categories
Funding
- Arisaph
- AstraZeneca
- Bristol-Myers Squibb
- Boehringer-Ingelheim
- GlaxoSmithKline
- Merck
- Takeda
- Amgen
- Kowa
- Lipimedix
- Pfizer
- Regeneron
- Sanofi
Ask authors/readers for more resources
Acute myocardial infarction has traditionally been divided into ST elevation or non-ST elevation myocardial infarction; however, therapies are similar between the two, and the overall management of acute myocardial infarction can be reviewed for simplicity. Acute myocardial infarction remains a leading cause of morbidity and mortality worldwide, despite substantial improvements in prognosis over the past decade. The progress is a result of several major trends, including improvements in risk stratification, more widespread use of an invasive strategy, implementation of care delivery systems prioritising immediate revascularisation through percutaneous coronary intervention (or fibrinolysis), advances in antiplatelet agents and anticoagulants, and greater use of secondary prevention strategies such as statins. This seminar discusses the important topics of the pathophysiology, epidemiological trends, and modern management of acute myocardial infarction, focusing on the recent advances in reperfusion strategies and pharmacological treatment approaches.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available